definiens: shall mean : ( a ) any antibody, peptide, or other l arge molecule, or small molecule, that activates or agonizes FGFR4 and ther eby inhibits liver Cyp7A1 expression, including NGM282, variants or derivatives of FGF19, and fusio n molecules of any such variants or der ivatives ; ( b ) any antibody, peptide, large molecule or small molecule compound that [ * ] ; or ( c ) any antibody, peptide, or other large molecule, or small molecule, licensed by NGM from a Third Party after the Effective Date, provided that such antibody, peptid e or other large molecule or small molecule : ( i ) do es not Modulate a Collaboration Target ( including any Optioned Target ) in a manner that satisfies the applicable Physiologically Relevant Threshold ; and ( ii ) was first licensed by NGM after such antibody, peptide or other large molecule, or small molecule, had been [ * ] . In no event will Retained Compounds include any antibody, peptide, or other large molec ule, or small molecule that is identified, discover ed or reduced to practice, or otherwise researched or developed, in the course of performing the Collaboration